Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib-Reference-Cited by-同舟云学术

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib

Published:2019-04 Issue: Volume:79 Page:38-44
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Gerds Aaron T.^ORCID,Tauchi Tetsuzo,Ritchie Ellen,Deininger Michael,Jamieson Catriona,Mesa Ruben,Heaney Mark,Komatsu Norio,Minami Hironobu,Su Yun,Shaik Naveed,Zhang Xiaoxi,DiRienzo Christine,Zeremski Mirjana,Chan Geoffrey,Talpaz Moshe

Funder

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. Myelofibrosis with myeloid metaplasia;Tefferi;N. Engl. J. Med.,2000

2. Are we altering the natural history of primary myelofibrosis?;Savona;Leuk. Res.,2014

3. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N. Engl. J. Med.,2012

4. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N. Engl. J. Med.,2012

5. Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? should it?;Barosi;Leukemia,2014

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer;Frontiers in Oncology;2024-04-18

2. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms;Cell Reports;2024-01

3. Inflammation and bone marrow fibrosis: novel immunotherapeutic targets;Current Opinion in Hematology;2023-08-02

4. Systematic dissection of coordinated stromal remodeling identifies Sox10 glial cells as a therapeutic target in myelofibrosis;Cell Stem Cell;2023-06

5. Myelofibrosis;Blood;2022-11-23